Update on therapy for refractory dermatomyositis and polymyositis

Current Opinion in Rheumatology

Volumn 8, Issue 6, 1996, Pages 544-551

  Villalba, Lourdes ^a   Adams, Elizabeth M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

BONE MARROW DEPRESSION; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; LYMPHOMA; MENINGITIS; MUSCLE BIOPSY; NEPHROTOXICITY; POLYMYOSITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SKIN CANCER; TREATMENT PLANNING;

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; METHYLPREDNISOLONE; POLYMYOSITIS; TACROLIMUS;

EID: 0030511865     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199611000-00008     Document Type: Review

References (61)

1. Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713. Update on inclusion body myositis.
2. Mader R, Keystone EC: Inflammatory myopathy: do we have adequate measures of the treatment response? [editorial]. J Rheumatol 1993, 20:1105-1107.
3. Oddis CV: Therapy of inflammatory myopathy. Rheum Dis Clin North Am 1994, 20:899-918.
4. Adams EM, Plotz PH: The treatment of myositis: how to approach resistant disease. Rheum Dis Clin North Am 1995, 21:179-202.
5. Tanimoto K, Nakano K, Kano S, et al.: Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995, 22:668-674.
6. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
7. Medsger TA Jr, Oddis CV: Classification and diagnostic criteria for polymyositis and dermatomyositis. J Rheumatol 1995, 22:581-585.
8. Oddis CV, Medsger TA Jr: Inflammatory myopathies. Baillieres Clin Rheumatol 1995, 9:497-514. A statistical analysis of various clinical criteria for dermato- and polymyositis in a well-defined patient population.
9. Bohan A, Peter JB: Polymyositis and dermatomyositis. N Engl J Med 1975, 292:344-347.
10. Engel AG, Hohlfeld R, Banker BQ: The polymyositis and dermatomyositis syndromes. In Myology. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw-Hill; 1994:1335-1384.
11. Goebels N, Michaelis D, Engelhardt M, et al.: Differential expression of perform in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996, 97:2905-2910.
12. Hagiwara E, Adams E, Plotz P, Klinman D: Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyosits. Clin Exp Rheumatol 14:485-491.
13. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994, 94:1729-1735.
14. Joffe MM, Love LA, Leff RL, et al.: Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387.
15. Henriksson KG, Lindvall B: Polymyositis and dermatomyositis 1990: diagnosis, treatment and prognosis. Prog Neurobiol 1990, 35:181-193.
16. Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV: A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995, 38:1218-1224. An analysis of long-term disabilities resulting from myositis and from treatment of myositis with corticosteroids.
17. Lee W, Zimmermann B, Lally EV: Relapse after prolonged remission in polymyositis: case report and literature review [abstract]. Arthritis Rheum 1996, 39:R25.
18. Ramirez G, Asherson RA, Khamashta MA, Cervera R, D'Cruz D, Hughes GR: Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum 1990, 20:114-120.
19. Lilley H, Dennett X, Byrne E: Biopsy proven polymyositis in Victoria 1982-1987: analysis of prognostic factors. J R Soc Med 1994, 87:323-326.
20. Newman ED, Scott DW: The use of low-dose methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol 1995, 1:99-102.
21. Dalakas MC: Treatment of polymyositis and dermatomyositis with steroids: a first therapeutic approach. In Eurorheumatology. Edited by Andriakanos A, Kappou I, Maurikakis M, Moutsopoulos H. Athens: Tagas; 1987:20-23.
22. Haller RG, Bertocci LA: Exercise evaluation of metabolic myopathies. In Myology. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw-Hill; 1994:807-821.
23. Martin L, Chalmers IM, Dhingra S, McCarthy D, Hunter T: Measurements of maximum respiratory pressures in polymyositis and dermatomyositis. J Rheumatol 1985, 12:104-107.
24. Hicks JE: Rehabilitating patients with idiopathic inflammatory myopathy. J Musculoskeletal Med 1995, 4:41-54. The specifics of rehabilitation by a physician who has assessed and followed up myositis patients for many years.
25. Hicks JE, Miller F, Plotz P, Chen TH, Gerber L: Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. J Rheumatol 1993, 20:1399-1401.
26. Escalante A, Miller L, Beardmore TD: Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol 1993, 20:1340-1344.
27. Klein-Gitelman M, Waters T, Pachman L: A comparison of the cost effectiveness of iv and po corticosteroids in the treatment of juvenile dermatomyositis (JDMS) [abstract]. Arthritis Rheum 1996, 39:R13.
28. Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H: Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994, 57:1008-1016.
29. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D: A comparison of low dose methotrexate bloavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993, 20:1845-1849.
30. Bittar B, Rose CD: Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis [letter]. Ann Rheum Dis 1995, 54:607-608.
31. Zieglschmid-Adams M, Pandya AG, Cohen SB, Sontheimer RD: Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol 1995, 32:754-757.
32. Villalba ML, Hicks JE, Thornton B, et al.: A combination of oral methotrexate and azathioprine is more effective than high dose intravenous methotrexate with leucovorin rescue in treatment-resistant myositis [abstract]. Arthritis Rheum 1995, 38:s307.
33. Blanco R, Martinez-Taboada VM, Gonzalez-Gay MA, et al.: Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996, 39:1016-1020.
34. Leff R, Miller F, Hicks J, Fraser D, Plotz P: The treatment of inclusion body myositis (IBM): a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993, 72:225-235.
35. Sussman GL, Pruzanski W: Treatment of inflammatory myopathy with intravenous gamma globulin. Curr Opin Rheumatol 1995, 7:510-515. A review of the pediatric and adult literature on IVIg for myositis.
36. Sabroe RA, Wallington TB, Kennedy CT: Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clin Exp Dermatol 1995, 20:164-167.
37. Cherin P, Piette JC, Wechsler B, et al.: Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994, 21:1092-1097.
38. Dalakas MC, Illa I, Dambrosia JM, et al.: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993, 329:1993-2000.
39. Cherin P, Herson S: Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994, 57(suppl):50-54.
40. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994, 121:259-262.
41. Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994, 44:223-226.
42. Sansome A, Dubowitz V: Intravenous immunoglobulin in juvenile dermatomyositis: four year review of nine cases. Arch Dis Child 1995, 72:25-28.
43. Vadanarayanan V, Subramony SH, Ray LI, Evans OB: Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin. Pediatr Neurol 1995, 13:336-339.
44. Reimold AM, Weinblatt ME: Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy. J Rheumatol 1994, 21:1144-1146.
45. Miller PW, Leitman SF, Cronin ME, et al.: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992, 326:1380-1384.
46. Cherin P, Auperin I, Bussel A, Pourrat J, Herson S: Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases [letter]. Clin Exp Rheumatol 1995, 13:270-271.
47. Faulds D, Goa KL, Benfield P: Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. [published erratum appears in Drugs 1993, 46:377.] Drugs 1993, 45:953-1040.
48. Alijotas J, Barquinero J, Ordi J, Vilardell M: Polymyositis and cyclosporin A [letter]. Ann Rheum Dis 1990, 49:66.
49. Sanchez Roman J, Castillo Palma MJ, Ocana Medina C, Wichmann I, Chinchon Lara I, Segura Ayestaran DI: The efficacy of cyclosporin in the treatment of myositis [in Spanish]. Rev Clin Esp 1995, 195:449-454.
50. Hamill G, Saunders C, Heckmatt J, Dubowitz V, Stanhope R: Catch-up growth in steroid dependent dermatomyositis treated with cyclosporin-A. Eur J Med 1992, 1:16-18.
51. Saadeh C, Bridges W, Burwick F: Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J 1995, 88:866-870.
52. Ando S, Kobayashi S, Yamanaka K, Takasaki Y, Hashimoto H: Successful combination therapy of cyclosporine and steroids in two cases with interstitial pneumonitis associated with polymyositis [in Japanese]. Ryumachi 1995, 35:95-99.
53. Larner AJ, Sturman SG, Hawkins JB, Anderson M: Myopathy with ragged red fibres following renal transplantation: possible role of cyclosporin-induced hypomagnesaemia. Acta Neuropathol (Berl) 1994, 88:189-192.
54. Oddis CV, Caroll P, Abu-Elmagd K, McCauley J, Fung JJ, Starzl TE: FK-506 in the treatment of polymyositis [abstract]. Arthritis Rheum 1994, 37:6(s):R19.
55. Sinoway P, Callen J: Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993, 36:319-324.
56. Gould JW, Mercurio MG, Elmets CA: Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995, 33:551-573.
57. Bloom BJ, Tucker LB, Klein-Gitelman M, Miller LC, Schaller JG: Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy [letter; comment]. J Rheumatol 1994, 21:2171-2172.
58. Person JR: Dermatomyositis responding to pentoxifylline. Br J Dermatol 1995, 134:593.
59. Konohana A, Kawashima J: Successful treatment of dermatomyositis with dapsone [letter]. Clin Exp Dermatol 1994, 19:367.
60. Palmieri GM, Sebes JI, Aelion JA, et al.: Treatment of calcinosis with diltiazem. Arthritis Rheum 1995, 38:1646-1654.
61. Griggs RC: Developing new treatments for muscle disease: prospects and promise. Curr Opin Neurol 1994, 7:422-426.